BPC-157 resists gastric juice, which is why it is sometimes sold in capsules. Resistance, however, is not the same thing as absorption. No published study, in animals or in humans, has measured what fraction of a swallowed dose reaches the bloodstream. The oral data come from rodent models and concern local action inside the digestive tract. Work on systemic action rests on injection, and even there a minority of the dose is absorbed. BPC-157 remains a research substance, not approved for human use.
Why do people say BPC-157 can be taken orally?
There is one reason: the molecule does not fall apart in the stomach. BPC-157 is a chain of fifteen amino acids rich in proline, without the usual cleavage sites for digestive enzymes. A 2014 paper described it as stable and resistant to hydrolysis and to enzymatic digestion. The first preclinical pharmacokinetic study of BPC-157, published in 2022, repeats that the peptide is resistant to hydrolysis, to enzymatic digestion and even to gastric juice. It follows that after swallowing, BPC-157 can reach the intestine intact.
That is a strong argument for oral dosing, but it covers only the survival of the molecule. It says nothing about how much of it crosses from the gut lumen into the blood.
What does “stable in gastric juice” mean, and what does it not mean?
Stability and absorption are two different phenomena. Stability means the peptide is not cut into inactive fragments by acid and enzymes. Absorption means it passes through the intestinal epithelium and enters the circulation. A molecule can be perfectly stable and still remain in the gut for the most part and be excreted. Large, water-loving peptides cross cell membranes poorly, and BPC-157 is exactly that kind of molecule.
What did the oral animal studies show?
Oral studies in rodents showed effects on the digestive tract itself. BPC-157 was dissolved in the drinking water of rats or given by gavage at doses in the range of 10 to 100 micrograms per kilogram. Faster healing of gastric ulcers, changes in markers of colitis and effects on intestinal permeability were recorded. All of these effects occur in tissue the peptide is in direct contact with. None of those studies demonstrated that an oral dose of BPC-157 reaches the Achilles tendon or the knee joint.
That distinction is the heart of the matter. Local action in the gut does not prove systemic action after swallowing.
How much BPC-157 is absorbed from an injection?
An intramuscular injection delivers a minority of the dose to the circulation, and it disappears quickly. In the 2022 study, absolute bioavailability after intramuscular injection was 14.5 to 19.4 per cent in rats and 45.3 to 50.6 per cent in dogs. The half-life was shorter than 30 minutes in both species. Four hours after dosing the peptide could no longer be detected in blood, and elimination went mainly through urine and bile. Even by the injected route, most of the dose in a rat does not reach the circulation intact.
| Parameter (2022 study) | Rat | Dog |
|---|---|---|
| Bioavailability after intramuscular injection | 14.5-19.4% | 45.3-50.6% |
| Oral bioavailability | not studied | not studied |
| Half-life | under 30 minutes | under 30 minutes |
| Detectable in blood | up to 4 hours | up to 4 hours |
Is there any human absorption data for BPC-157?
There is no human data at all. The first preclinical pharmacokinetic paper on BPC-157 appeared only in 2022 and covered rats and dogs. A phase one study of a BPC-157 preparation in healthy volunteers is listed in the registry as withdrawn. That means zero measurements of absorption, blood concentration and duration of action in a human being, for the oral route and for the injected route alike. The state of research on BPC-157 itself is covered in a separate article on what the research on BPC-157 shows.
What about the BPC-157 capsules on sale?
BPC-157 capsules are sold as a research product, without evidence that they deliver the peptide to the blood. A manufacturer of that form presents no bioavailability data, because no such data exist. In this shop BPC-157 is stocked as a lyophilised powder for reconstitution rather than in capsules, and also as a ready blend with TB-500. Preparing the solution is described in the article on reconstituting a peptide with bacteriostatic water. Whatever the route of administration, BPC-157 is not approved for human use and appears on the WADA prohibited list among non-approved substances. The legal warning page sets out the details of that status.
Frequently asked questions
Is BPC-157 absorbed after swallowing?
Nobody knows, because nobody has measured it. The resistance of BPC-157 to gastric juice means only that the molecule is not digested. It is not proof that it crosses from the gut lumen into the blood.
What is the difference between local and systemic action?
Local action takes place in the tissue the peptide is in contact with, for example the intestinal wall. Systemic action requires travel through the blood to a distant tissue, for example a tendon. The oral animal studies show only the first of these.
How much BPC-157 is absorbed from an injection?
In the 2022 study, bioavailability after intramuscular injection was about 14.5 to 19.4 per cent in rats and 45.3 to 50.6 per cent in dogs. The half-life was shorter than 30 minutes, and after 4 hours the peptide was undetectable in blood.
Are there human absorption studies of BPC-157?
No. The first pharmacokinetic study, from 2022, covered rats and dogs. The phase one study in humans is listed in the registry as withdrawn, so there is no human absorption data.
Are BPC-157 capsules a medicine?
No. They are a product intended for research, without registration as a medicine and without data showing that they deliver the peptide to the bloodstream. BPC-157 is also prohibited in sport at all times.